Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 10450 participants.
Also called NCT07157774
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 10,450 participants
- Sponsor
- Registry
-
NCT07157774 -
2025-521067-13-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czechia, Denmark, France, Germany, Greece, Hungary, India, Italy, Japan, Mexico, Netherlands, Poland, Puerto Rico, Romania, Singapore, Slovakia, South Korea, Spain, Taiwan, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07157774. Randomized; double masking; primary purpose treatment. Start 2025-09-02 (actual); primary completion 2031-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a)
- Acronym
- MOVE-Lp(a)
- Condition
- Elevated Lp(a)
- Condition
- Atherosclerotic Cardiovascular Disease (ASCVD)
- Intervention (Drug)
- Muvalaplin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Eli Lilly and Company
Record details
- Record id
cardio:ct-nct07157774- Content hash
08aa74430c2cfebc6bcafd64130a38b75cae52169a700d1cff259976c68c6bfd